242 related articles for article (PubMed ID: 38155967)
21. A novel telomere-related genes model for predicting prognosis and treatment responsiveness in diffuse large B-cell lymphoma.
Zhao Z; Shen X; Zhao S; Wang J; Tian Y; Wang X; Tang B
Aging (Albany NY); 2023 Nov; 15(22):12927-12951. PubMed ID: 37976136
[TBL] [Abstract][Full Text] [Related]
22. A prognostic gene model of immune cell infiltration in diffuse large B-cell lymphoma.
Zhou H; Zheng C; Huang DS
PeerJ; 2020; 8():e9658. PubMed ID: 32844062
[TBL] [Abstract][Full Text] [Related]
23. A novel angiogenesis-related scoring model predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma.
Liu Y; Wang J; Shen X; Li L; Zhang N; Wang X; Tang B
Clin Exp Med; 2023 Nov; 23(7):3781-3797. PubMed ID: 37402040
[TBL] [Abstract][Full Text] [Related]
24. Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.
Zhang Q; Zhu Z; Guan J; Zheng C
Front Oncol; 2022; 12():904614. PubMed ID: 35814424
[TBL] [Abstract][Full Text] [Related]
25. Ferroptosis Markers Predict the Survival, Immune Infiltration, and Ibrutinib Resistance of Diffuse Large B cell Lymphoma.
Weng J; Chen L; Liu H; Yang XP; Huang L
Inflammation; 2022 Jun; 45(3):1146-1161. PubMed ID: 35064379
[TBL] [Abstract][Full Text] [Related]
26. What factors are associated with the prognosis of primary testicular diffuse large B-cell lymphoma? A study based on the SEER database.
Yang S; Chang W; Zhang B; Shang P
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10269-10278. PubMed ID: 37270733
[TBL] [Abstract][Full Text] [Related]
27. The Dark Side of Pyroptosis of Diffuse Large B-Cell Lymphoma in B-Cell Non-Hodgkin Lymphoma: Mediating the Specific Inflammatory Microenvironment.
Wang W; Xu SW; Teng Y; Zhu M; Guo QY; Wang YW; Mao XL; Li SW; Luo WD
Front Cell Dev Biol; 2021; 9():779123. PubMed ID: 34805183
[No Abstract] [Full Text] [Related]
28. Development and validation of a [
Li M; Yao H; Zhang P; Zhang L; Liu W; Jiang Z; Li W; Zhao S; Wang K
Eur Radiol; 2023 May; 33(5):3354-3365. PubMed ID: 36547676
[TBL] [Abstract][Full Text] [Related]
29. Identification of Aging-Related Genes Associated with Prognostic Value and Immune Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.
Luo C; Nie H; Yu L
Oxid Med Cell Longev; 2022; 2022():3334522. PubMed ID: 35069971
[TBL] [Abstract][Full Text] [Related]
30. A novel prognostic signature based on immune-related genes of diffuse large B-cell lymphoma.
Wu Z; Guan Q; Han X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Wang X; Zhang H
Aging (Albany NY); 2021 Oct; 13(19):22947-22962. PubMed ID: 34610582
[TBL] [Abstract][Full Text] [Related]
31. Identification of a prognostic signature based on five ferroptosis-related genes for diffuse large B-cell lymphoma.
Li W; Yao R; Yu N; Zhang W
Cancer Biomark; 2024; 40(1):125-139. PubMed ID: 38517778
[TBL] [Abstract][Full Text] [Related]
32. Identification of an individualized RNA binding protein-based prognostic signature for diffuse large B-cell lymphoma.
Xie Y; Luo X; He H; Pan T; He Y
Cancer Med; 2021 Apr; 10(8):2703-2713. PubMed ID: 33749163
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of a combined cuproptosis and immunogenic cell death prognostic model for diffuse large B-cell lymphoma.
Wang N; Shi S; Li M; Yu X; Ma G
Aging (Albany NY); 2024 Jan; 16(2):1218-1236. PubMed ID: 38284893
[TBL] [Abstract][Full Text] [Related]
34. International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.
Mu S; Shi D; Ai L; Fan F; Peng F; Sun C; Hu Y
Front Immunol; 2021; 12():732006. PubMed ID: 34745101
[TBL] [Abstract][Full Text] [Related]
35. [Establishment and Clinical Significance of Prognostic Nomogram Model for Diffuse Large B-Cell Lymphoma Based on Immunohistochemistry Markers and International Prognostic Index Scores].
Xu YW; Zhou YL; Kong FC; Chen ZW; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):753-761. PubMed ID: 37356936
[TBL] [Abstract][Full Text] [Related]
36. The fatty acid-related gene signature stratifies poor prognosis patients and characterizes TIME in cutaneous melanoma.
Hua S; Wang W; Yao Z; Gu J; Zhang H; Zhu J; Xie Z; Jiang H
J Cancer Res Clin Oncol; 2024 Jan; 150(2):40. PubMed ID: 38279987
[TBL] [Abstract][Full Text] [Related]
37. High Expression of CISD2 in Relation to Adverse Outcome and Abnormal Immune Cell Infiltration in Glioma.
Zhang F; Cai HB; Liu HZ; Gao S; Wang B; Hu YC; Cheng HW; Liu JX; Gao Y; Hong WM
Dis Markers; 2022; 2022():8133505. PubMed ID: 35493303
[TBL] [Abstract][Full Text] [Related]
38. A novel anoikis-related signature predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma.
Guan M; Zhao H; Zhang Q; Li L; Wang X; Tang B
Expert Rev Mol Diagn; 2024 May; 24(5):439-457. PubMed ID: 38709202
[TBL] [Abstract][Full Text] [Related]
39. Predictive Modelling of Overall Survival in Adult Patients with Primary Diffuse Large B-cell Lymphoma of the Breast Using the Surveillance, Epidemiology, and End Results (SEER) Database.
Liu Y; Han H; Wei H; Wang X; Luan Z; Jiang K
Recent Pat Anticancer Drug Discov; 2024; 19(3):373-382. PubMed ID: 37464821
[TBL] [Abstract][Full Text] [Related]
40. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
